VivoSeq
Oncology

Pancreatic Ductal Adenocarcinoma

153

Pipeline Programs↗

55

Active Trials↗

62

Companies Involved↗

Pancreatic Ductal Adenocarcinoma is a highly competitive landscape with 153 programs across 62 companies. The most active players are SONIRE Therapeutics Inc., Incyte, Gilead. 4 therapies are approved with 25 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

78/100

Pipeline Velocity

49/100

Mech. Concentration

6/100

Completion Rate

55/100

Attrition Rate

18/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

S

SONIRE Therapeutics Inc.

3 programs

Phase 1Incyte logo

Incyte

3 programs

Phase 1Gilead logo

Gilead

2 programs

Phase 1P

ProDa BioTech, LLC

1 program

Phase 1Eisai logo

Eisai

1 program

Phase 1Bayer logo

Bayer

1 program

Phase 1

Pipeline

Programs by Phase

Preclinical6

Adjuvant Chemotherapy

Nizhny Novgorod Regional Clinical Oncology Center

Combination Therapy With Meki.

Mandana Kamgar, MD

[203pb]pb-PSV359

Perspective Therapeutics

[212pb]pb-PSV359

Perspective Therapeutics

AG/FOLFIRINOX

Luo Cong

Phase 151

Canakinumab

Novartis

Retifanlimab

Incyte

Spartalizumab

Novartis

Lenvatinib

Eisai

Ruxolitinib

Incyte

Phase 267

Cisplatin

McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Tremelimumab

AstraZeneca

Paricalcitol

AbbVie

Rucaparib

Bristol-Myers Squibb

Abemaciclib

Eli Lilly

Phase 325

Momelotinib

Glaxo Dba Glaxosmithkline

Irinotecan Hydrochloride

Eastern Cooperative Oncology Group

Paclitaxel

Teva

Telisotuzumab Adizutecan

AbbVie

Fluorouracil

Elorac, Inc.

Approved4

Chlorambucil

Akero Therapeutics

Vismodegib

Roche

Doxorubicin

Pfizer

Sitagliptin

Zydus Therapeutics Inc.

Analysis

Modality Breakdown

80%

Small molecule

126 of 157 classified programs — the dominant modality here.

20%ALL OTHERSMonoclonal antibody2113%Protein / enzyme32%Cell therapy32%Peptide21%Vaccine1<1%Radiopharmaceutical1<1%

Small molecule leads; the ring shows all 157 classified programs, each share of the total. Modality classified for 97% of 167 pipeline programs.

Analysis

Trial Status

101

clinical trials

Recruiting29 · 29%
Completed22 · 22%
Active, not recruiting16 · 16%
Terminated14 · 14%
Not yet recruiting10 · 10%
Unknown status5 · 5%
Other5 · 5%

Clinical Trials

Trial Activity

101 trials

A Registry to Capture Patient Outcomes With KRAS G12R Altered Advanced Pancreatic Ductal Adenocarcinoma Treated With MEK Inhibitor-based Combination Therapy
Recruiting·MMandana Kamgar, MD·N/A·NCT05630989·80 enrolled
Utility of ctDNA in Early Switch of First-line mFOLFIRINOX in Metastatic Pancreatic Ductal Adenocarcinoma
Recruiting·UUniversity of Miami·Phase 2·NCT07096362·50 enrolled
MK2 Inhibitor in Combination With mFOLFIRINOX for Untreated Metastatic Pancreatic Ductal Adenocarcinoma
Recruiting·WWashington University School of Medicine·Phase 1·NCT06648434·51 enrolled
To Evaluate the Safety and Efficacy of RNK08954 in Patients With Metastatic Pancreatic Ductal Adenocarcinoma.
Recruiting·RRanok Therapeutics (Hangzhou) Co., Ltd.·Phase 2·NCT07303465·60 enrolled
OMO-103 for the Treatment of Locally Advanced or Metastatic Pancreatic Ductal Adenocarcinoma
Recruiting·OOHSU Knight Cancer Institute·Phase 1·NCT07089940·12 enrolled
PTM-101 in Pancreatic Ductal Adenocarcinoma (PDAC)
Recruiting·—·Phase 1·NCT06673017·26 enrolled
Monthly Alternating NALIRIFOX and GnP in the First-Line Setting for Metastatic Pancreatic Ductal Adenocarcinoma
Recruiting·NNorthwell Health·Phase 2·NCT07163273·41 enrolled
A Study of NALIRIFOX in Combination With Radiation Therapy in People With Pancreatic Ductal Adenocarcinoma (PDAC)
Recruiting·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT05851924·60 enrolled
Combination Therapy in Patients With Localized Pancreatic Ductal Adenocarcinoma
Recruiting·—·Phase 2·NCT06048484·60 enrolled
A Study Comparing BMS-986504 in Combination With Nab-paclitaxel and Gemcitabine Versus Placebo in Combination With Nab-paclitaxel and Gemcitabine in Participants With Untreated Metastatic Pancreatic Ductal Adenocarcinoma With Homozygous MTAP Deletion (MountainTAP-30)
Recruiting·Bristol-Myers Squibb logoBristol-Myers Squibb·Phase 2/3·NCT07076121·470 enrolled
A Study of CEND-1 With Chemotherapy as First-Line Therapy in Patients With Pancreatic Ductal Adenocarcinoma
Recruiting·Qilu Pharmaceutical Co., Ltd. logoQilu Pharmaceutical Co., Ltd.·Phase 2·NCT06261359·120 enrolled
Intraperitoneal Paclitaxel With NALIRIFOX for Pancreatic Ductal Adenocarcinoma With Peritoneal Carcinomatosis
Recruiting·UUniversity of Colorado, Denver·Phase 1·NCT07030283·10 enrolled
ProAgio in Pancreatic Ductal Adenocarcinoma (PDAC)
Recruiting·PProDa BioTech, LLC·Phase 1·NCT06182072·46 enrolled
NALIRIFOX Before Surgery for the Treatment of Borderline Resectable Pancreatic Ductal Adenocarcinoma, Nectar Trial
Recruiting·RRoswell Park Cancer Institute·Phase 2·NCT06821997·20 enrolled
Investigational Scan (68Ga-FAPI-46 PET/CT) for Imaging of Cancer-Associated Fibroblasts for Localized Pancreatic Ductal Adenocarcinoma
Recruiting·MMayo Clinic·Phase 2·NCT05518903·130 enrolled
Page 1 of 7

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)